Skip to main content
. 2021 Dec 21;15:15–28. doi: 10.1016/j.bioactmat.2021.12.020

Fig. 7.

Fig. 7

NP/mDs boosted host immunity for in vivo antitumor treatment. (a) Immunoblot analysis of p53, Bcl-2, and caspase 3 of CT26 syngeneic tumors after Q3D × 5 chemotherapy and/or immunotherapy. β-actin was used as the loading control. (b) CT26 syngeneic tumors after treatment displayed the exposure of ICD makers and the recruitment of APCs. Scale bar = 100 μm. Percentage of (c) mature DCs, (d) CD8+ T cells, (e) CD4+ T cells, and (f) Treg cells infiltrated in CT26 syngeneic tumors after mice i.v injected with NP/mDs and each component, and/or i.p. injected with αPD-L1 in a Q3D × 5 schedule, n = 4. Release of (g) IL-12 and (h) IFN-γ in CT26 syngeneic tumors, n = 3. (i) Schematic representation of dying CT26 cell attenuation and live CT26 cell re-challenge in immunocompetent BALB/c mice for antitumor vaccination evaluation. (j) Percentage of BALB/c mice with tumor-free on the contralateral flank after live CT26 cell re-challenge, n = 6. Data points in c-h represent mean ± SD. Statistical significance was calculated by ANOVA with Tukey's test. n.s., not significant, *p < 0.05, **p < 0.01, and ***p < 0.001.